Evaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.

Recruiting

Phase 1

Phase 2

GeminiEvaluation of the Safety and Tolerability of Gemini in Subjects With Stage 3-4 Chronic Kidney Disease.

Sponsor:

Revelation Biosciences, Inc

Code:

NCT06863467

Conditions

Renal Insufficiency, Chronic

Chronic Kidney Disease stage3

Chronic Kidney Disease stage4

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Intravenous Gemini

Intravenous placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-08-16. This information was provided to ClinicalTrials.gov by Revelation Biosciences, Inc on 2025-03-07.